Other
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Moderna Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss decreased by 4.2% to $271M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 80.0%, from $1.36B to $271M. Over 4 years (FY 2021 to FY 2025), Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss shows an upward trend with a 310.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
First reportedQ4 2018
Last reportedQ1 2026May 1, 2026
Metric ID:
other_debt_securities_available_for_sale_continuous_unre_23ad4cHistorical Data
18 periods
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1M | $1M | $517M | $3.65B | $5.52B | $7.7B | $8.15B | $7.4B | $6.64B | $5.1B | $4.8B | $3.58B | $2.64B | $1.36B | $567M | $499M | $283M | $271M |
| QoQ Change | — | +0.0% | >999% | +605.2% | +51.5% | +39.4% | +5.9% | -9.2% | -10.2% | -23.3% | -5.8% | -25.5% | -26.1% | -48.7% | -58.2% | -12.0% | -43.3% | -4.2% |
| YoY Change | — | — | — | — | >999% | >999% | >999% | +103.0% | +20.3% | -33.8% | -41.1% | -51.7% | -60.2% | -73.4% | -88.2% | -86.1% | -89.3% | -80.0% |
Range$1M – $8.15B
CAGR+273.6%
Avg YoY Growth>999%
Median YoY Growth-46.4%
Current Streak11 quarters decline
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss at Other Companies
Frequently Asked Questions
- What is Moderna's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss?
- Moderna (MRNA) reported debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss of $271M in Q1 2026.
- How has Moderna's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss changed year-over-year?
- Moderna's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss decreased by 80.0% year-over-year, from $1.36B to $271M.
- What is the long-term trend for Moderna's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss?
- Over 4 years (2021 to 2025), Moderna's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss has grown at a 310.2% compound annual growth rate (CAGR), from $1M to $283M.